Frazier Life Sciences Management, LP
Frazier Life Sciences XI, L.P.
Late investment period: first sale Mar 2022, per Form D (fund age approximates vintage)
- Vintage
- 2022
- Fund size
- $960M (Form D)
- Stages
- Seed, Series A, Growth
- Sectors
- Biotech
- Regions
- Global
01 · Thesis
Frazier Life Sciences backs early-stage private biopharmaceutical companies developing novel therapeutics, with an emphasis on company creation and Series A investments, often building product-focused companies and partnering with management over the long term.Inferred from the firm's website
02 · Initial check
$9.6M to $16M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Patrick Heron, Member of the General Partner of the General Partner
- James N. Topper, M.D., Ph.D., Managing Partner
- Daniel Estes, Ph.D., General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Firm-wideA venture fund focused on early-stage private biopharmaceutical companies, with an emphasis on company creation and Series A investments.
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
https://frazierls.com/news/Firm-wideLongstanding healthcare investment firm partnering with and building companies developing novel therapeutics from seed to publics.
Longstanding healthcare investment firm partnering with and building companies developing novel therapeutics from seed to publics.
https://frazierls.com/
06 · Sources
Last verified: Oct 28, 2026